Specific antioxidant compounds differentially modulate cytotoxic activity of doxorubicin and cisplatin: \textit{in vitro} and \textit{in vivo} study

\textbf{Aim} To use the antioxidant compounds (sodium selenite, selenomethionine, D-pantethine) for modulation of cytotoxic effect of doxorubicin and cisplatin toward wild type and drug-resistant mutants of several human tumor cells. Similar treatments were applied \textit{in vivo} toward adult male Wistar rats.

\textbf{Methods} Human tumor cells of different lines (HCT-116, Jurkat and HL-60) with various mechanisms of drug-resistance were treated with doxorubicin or cisplatin, alone or in combination with sodium selenite, selenomethionine, or D-pantethine. Cell viability, induction of apoptosis, and production of $O_2^-$ radicals were measured. Activity of redox potential modulating enzymes was measured in the liver and blood plasma of adult male Wistar rats subjected to similar treatments.

\textbf{Results} All antioxidants used in physiologically harmless concentration inhibited cytotoxic action of doxorubicin toward tumor cells sensitive to chemotherapy treatment by 15\%-30\%, and slightly enhanced cytotoxic effect of this medicine toward drug-resistant malignant cells. At the same time, there was no significant effect of these antioxidants on cisplatin action. Such effects were accompanied by a complete inhibition of production of superoxide radicals induced by doxorubicin. The results of \textit{in vivo} study in adult male Wistar rats were in agreement with the results of \textit{in vitro} study of human tumor cells.

\textbf{Conclusion} Protective effect of specific antioxidant agents during cytotoxic action of doxorubicin was demonstrated \textit{in vitro} in drug-sensitive human tumor cells and in adult male Wistar rats, while there was no protective effect in drug-resistant sub-lines of these tumor cells during action of doxorubicin and cisplatin.
Low selectivity of action of the chemotherapeutic agents is one of their main shortcomings, leading to serious negative side effects in cancer patients. The main reason for this phenomenon is the formation of free radicals during the action of these drugs in both normal and tumor cells. Doxorubicin and cisplatin are among the most commonly used anticancer drugs. They realize the antineoplastic activity by the intercalation into DNA structure and production of the reactive oxygen species (ROS) (1-3). However, these drugs lead to severe cardio- and nephrotoxicity, which significantly limits their use for tumor treatment (4). It was shown that side effects of doxorubicin and cisplatin are mediated by hydroxyl radicals, which are formed in the presence of iron (II) from superoxide anions whose production is induced by these drugs (3,5). Numerous studies indicate that ROS-induced apoptosis of tumor cells takes place only under supraclinical doses of anthracyclines, and ROS production is not critical for realization of their antitumor activity (3). Thus, selective blocking of ROS action by specific antioxidant agents should at least partially reduce the toxicity of doxorubicin and cisplatin toward normal cells, without significant impact on the antitumor action of these drugs. Promising candidates for such role are derivatives of the pantothenic acid, since they possess significant antioxidant effect toward the mammalian cells and are able to protect the cells against toxic effects of free radicals (6). The inorganic and organic selenium derivatives (sodium selenite and selenomethionine) belong to another group of antioxidants that demonstrated a protective effect during cisplatin chemotherapy (7,8). Similar protective effects were also observed for the pantothentic acid (9). However, it remains unknown whether these antioxidants are capable of inhibiting the production of harmful ROS (including superoxide and hydroxyl radicals) due to the action of anticancer agents, and at the same time not interfering with the anti-tumor activity of these drugs. Besides, the effect of D-pantethine, selenomethionine, and sodium selenite used in combination with the anticancer drugs toward tumor cells resistant to chemotherapy has not been studied thoroughly (10).

In this study, we aimed to develop new approaches for cancer chemotherapy that would eliminate negative side effects of the anticancer drugs caused by an excessive production of free radicals, which adversely affect normal tissues and organs in cancer patients. A chemotherapy regimen based on a combination of specific antioxidants (sodium selenite, selenomethionine, D-pantethine) and conventional anticancer drugs (doxorubicin, cisplatin), which are known to induce production of ROS, has been proposed. We studied the molecular mechanisms of antitumor activity of doxorubicin and cisplatin combined with the antioxidants toward tumor cell lines possessing different mechanisms of drug resistance. The results obtained in the in vitro study have been verified in experimental animals (rats).

**MATERIALS AND METHODS**

The study was conducted at the Institute of Cancer Research Vienna, Austria, the Institute of Cell Biology, Lviv, Ukraine, and the Center of Food, National Academy of Sciences of Belarus in Grodno in 2013. Human isogenic p53-null (p53−/−), Bax-null (Bax−/−), and wild-type (p53+/+, Bax+/+) human HCT-116 colon carcinoma cells (kindly provided by Dr Bert Vogelstein), human breast adenocarcinoma cells of MCF-7 line, human T-lymphocytes cells of Jurkat line, human leukemia cells of HL-60 line, and its drug-resistant HL-60/vinc sub-line (overexpression of P-glycoprotein) were obtained from cell culture collection at the Vienna Medical University, Institute of Cancer Research. Cells were cultured in RPMI-1640 medium, supplemented with 10% fetal calf serum (Sigma Chemical Co., St. Louis, MO, USA), 50 µg/mL streptomycin (Sigma Chemical Co.), and 50 units/mL penicillin (Sigma Chemical Co.) in 5% CO₂-containing humidified atmosphere at 37°C. Cells were seeded into 24-well tissue culture plates (Greiner Bio-one, Frickenhausen, Germany). Short-term (24 hours) cytotoxic effect of anticancer drugs was studied under the Evolution 300 Trino microscope (Delta Optical, Mińsk Mazowiecki, Poland) after cell staining with Trypan blue (0.1%).

To analyze cytotoxic activity of conventional anticancer drugs together with non-toxic doses of the antioxidants in vitro, tumor cell lines possessing various mechanisms of resistance to anticancer drugs were studied. For estimating the impact of the antioxidants on cytotoxic activity of conventional anticancer drugs, semi-lethal doses of cisplatin and doxorubicin causing death of 50% of malignant cell were used in combination with non-toxic doses of the antioxidants. The effect of antioxidants that led to a 5%-10% (statistically unreliable) decrease in cytotoxic activity of drugs was considered weak, the effect that led to a decrease of 15%-30% was considered moderate, and that which led to a decrease of 30%-50% was considered strong.

The cells were stained with DAPI (4',6-diamidino-2-phenylindole) (Sigma) for studying chromatin con-
densation in the MCF-7 cells treated with doxorubicin and antioxidants. 24 hours after the addition of drugs, MCF-7 cells were washed twice with 1x PBS, fixed for 15 minutes at room temperature in 4% solution of parafomaldehyde, and permeabilized for 3 minutes with 0.1% Triton X-100 in the phosphate buffer saline (PBS). After that, cells were incubated for 5 minutes with 1 µg/mL solution of DAPI (Sigma), washed twice with PBS, and cover glasses with fixed cells were placed on slides. Cytomorphological study was performed under Carl Zeiss Axiolmager A1 fluorescent microscope (Carl Zeiss, Göttingen, Germany).

The content of the ROS was measured after incubation of control or drug-treated (24 hours) MCF-7 cells with fluorescent dye dihydroethidium (DHE, O$_2^{•−}$-specific) used in 10 µM concentration for 30 minutes at 37°C. After incubation with fluorochrome, cover glasses with cells were washed with PBS and placed on slides, and the intensity of fluorescence was immediately analyzed under Carl Zeiss Axiolmager A1 fluorescent microscope (Carl Zeiss).

Thirty-two adult male Wistar CRL rats with 90-110 g weight were kept under standard vivarium conditions with constant access to the full feed and drinking water. Animals were divided into 4 groups of 8 rats each. Rats from experimental groups were intragastrically administered D-pantethine 400 mg/kg (group 3) and selenomethionine 200 µ/kg (group 4) for 5 days. Rats from the first (control) group were injected simultaneously with equivalent volume of 0.9% sodium chloride solution in a similar mode. Doxorubicin (5 mg/kg) was injected once i.p. to the animals from 2-4th groups in 3 days before decapitation.

All in vivo experiments were conducted in accordance with the international principles of the European Convention for protection of vertebrate animals under a control of the Bio-Ethics Committee of the Center of Food, National Academy of Sciences of Belarus in Grodno.

The activity of glutathione reductase and glutathione transferase was measured according to Carlberg et al (11,12). Glutathione and its redox potential in erythrocytes was determined as previously described (13). Products that react with N, N-dimethyl-p-phenylenediamine in plasma were detected as previously described (14). Analysis of free SH-groups in proteins from blood plasma was done as previously described (15).

**FIGURE 1.** Sodium selenite, selenomethionine, and D-pantethine decrease cytotoxic action of doxorubicin toward wild-type HCT-116 cells, but have no impact on doxorubicin action toward HCT-116/Bax(−/−) and HCT-116/p53(−/−) sub-lines lacking Bax and p53 genes. Medium – blank control (appropriate volume of culture medium added instead of the antioxidants). *P<0.05 relative to the control. A – P = 0.0098, B – P = 0.0211, C – P = 0.0321.
Activity of succinate dehydrogenase and 2-oxoglutarate dehydrogenase was measured spectrophotometrically (16). Sorption reaction with Nile blue dye was used as a functional test of the biological stability of erythrocyte membranes, as previously described (17). The level of adsorption in erythrocytes was measured by using methylene blue assay (18).

Identification of coenzyme A (CoA) fractions was conducted as previously described (19,20). The content of free form of CoA (CoA-SH) and short chain acyl-CoA derivative (acetyl-CoA) in the rat liver was determined using HPLC assay on a HPLC instrument Agilent 1100/1200 (Agilent Technologies, Santa Clara, CA, USA). Homogenization of liver tissue samples was performed at 4°C using 4% HClO₄ at a ratio of 1:6. The homogenates were centrifuged at 16,000 g for 15 minutes at 4°C and the obtained chloride supernatants were adjusted to pH 5 with 20% NaOH. Prior to introduction into the chromatograph, the supernatant was filtered through a RC 0.45 μm, 13 mm filter (Agilent Technologies). Chromatographic column Zorbax SB-C₁₈ 150x3 mm, particle size 3.5 µm (Agilent Technologies) was used for HPLC.

All experiments were performed in triplicate and repeated 3 times. For statistical analysis, standard variation data within a group were calculated together with a statistical reliability of differences between two groups of data assessed by t-test. The level of significance was set to 0.05.

**RESULTS**

Differential effect of antioxidants toward cytotoxic action of doxorubicin in drug-sensitive and drug-resistant tumor cell lines

Human colon carcinoma cells of HCT-116 wild-type line (with intact copies of the p53 and Bax genes) and its sub-lines HCT-116 (Bax (−/−) and HCT-116/p53 (−/−) characterized by a knockout of Bax and p53 genes, respectively, were chosen as an experimental model. Deletion of Bax gene resulted in a 2-fold increase in the resistance of these cells to doxorubicin action, whereas a deletion of the p53 gene did not affect this parameter (Figure 1). Sensitivity to sodium selenite and selenomethionine in HCT-116 wild-type cells and its gene knockout HCT-116/
p53 (−/−) and HCT-116/Bax (−/−) sub-lines was almost identical. These compounds used in 0.1-0.25 µM doses were completely non-toxic toward the studied cell lines (Figure 1). All applied antioxidants demonstrated moderate cytoprotective action, decreasing by 15%-20% the cytotoxic effect of doxorubicin toward HCT-116 cells (Figure 1). On the contrary, sodium selenite and selenomethionine in the same dose (0.1 µM) did not protect HCT-116/Bax (−/−) and HCT-116/p53 (−/−) sub-lines, while in a higher and still non-toxic concentration (0.25 µM) they only slightly intensified doxorubicin action (Figure 1). Surprisingly, HCT-116/p53 (−/−) cells were hypersensitive to D-pantethine action, and thus 20 times lower concentrations of this antioxidant (1 µM and 2.5 µM) were used compared to doses applied toward wild-type cells (25 µM and 50 µM, respectively). However, even in these low doses, D-pantethine did not act cytoprotectively toward HCT-116/p53 (−/−) and HCT-116/Bax (−/−) cells, while it protected HCT-116/wt cells with the same or even higher efficiency than did the selenium derivatives. Thus, antioxidants seem to protect against toxic effect of doxorubicin only drug-sensitive tumor cells, and have no impact on cytotoxic action of doxorubicin toward tumor cells with impaired structure of Bax and p53 genes.

In order to confirm the obtained results, human leukemia cells of HL-60 line and its drug-resistant HL-60/vinc sub-line characterized by an overexpression of P-glycoprotein, were used. HL-60 cells are very sensitive to doxorubicin action (LC₅₀ = 0.5 µM), and sodium selenite, selenomethionine, and D-pantethine demonstrated weak protective effect against the action of this anticancer drug (Figure 2). In contrast, the cells of HL-60/vinc sub-line showed a 10-fold increase in their resistance to doxorubicin, while all applied antioxidants failed to have a protective effect in these cells (Figure 2). Human T-leukemia cells of Jurkat line were most sensitive to doxorubicin action, and they also responded distinctly on the protective action of sodium selenite, selenomethionine, and D-pantethine (Figure 2). In particular, sodium selenite in 0.05 µM dose or D-pantethine in 25 µM dose acting together with doxorubicin in its LC₅₀ dose (0.5 µM) toward Jurkat T-cells significantly recovered the cell population to 78%-80% of the control level, while the effect of selenomethion-
In contrast to doxorubicin action, there was no cytoprotective effect of the antioxidants in the case of cisplatin action. A combined treatment of Jurkat T-leukemia cells with LC$_{50}$ dose of cisplatin (10 µM) and 0.1 µM of sodium selenite led to only a 4% decrease in cisplatin cytotoxicity, while selenomethionine and D-pantethine had no effect at all (Figure 3). The same lack of effect was observed in the case of HL-60 leukemia cells, as well as its drug-resistant HL-60/vinc sub-line (Figure 3). There was only a weak cytoprotective effect of sodium selenite of 7%, and a lack of effect of selenomethionine and D-pantethine toward cisplatin cytotoxic action in the parental HCT-116 cell line, as well as its drug-resistant Bax(−/−) and p53(−/−) sub-lines (Figure 4). Thus, drug-resistant tumor cells compared with drug-sensitive tumor cells showed much weaker sensitivity to cisplatin action, which is similar to a decreased sensitivity to antioxidants’ action in the case of doxorubicin.

**Antioxidants inhibit ROS production and apoptosis induced by doxorubicin in tumor cells**

Sodium selenite, selenomethionine, and D-pantethine only partially (15%-30%) suppressed cytotoxic activity of doxorubicin in drug-sensitive tumor cells (Figure 1,2). Since ROS production is a supplementary pathway in apoptosis induced by doxorubicin (3), it is obvious that the observed effect of antioxidants is explained by the inhibition of production of superoxide anions under the doxorubicin treatment.

Next, we attempted to confirm the results obtained at the molecular level by studying the production of the superoxide radicals in human breast adenocarcinoma cells of MCF-7 line under the action of doxorubicin and the antioxidants (Figure 5A). Doxorubicin (1 µM) caused a 10-fold increase in the production of superoxide anion compared...
to control (untreated cells), whereas addition of sodium selenite (0.1 µM) reduced ROS production to nearly baseline level. Selenomethionine (0.1 µM) and D-pantethine (25 µM) showed weaker but also pronounced inhibitory effect on ROS levels in MCF-7 cells (Figure 5A). Therefore, all applied antioxidants acted by inhibiting the production of superoxide anion in target tumor cells.

It is known that ROS are involved in the induction and regulation of apoptosis signaling pathways in various (including tumor) cells (21,22). To ensure that antioxidants’ inhibition of production of superoxide anions induced by doxorubicin can also lead to further suppression of apoptosis, cytomorphological study of human breast adenocarcinoma cells of MCF-7 line under the action of doxorubicin in combination with the antioxidants was performed (Figure 5B). Doxorubicin (1 µM) caused a development of typical apoptosis hallmarks – hypercondensation of nuclear chromatin and cell contraction, whereas sodium selenite almost completely restored the cytomorphological phenotype of MCF-7 cells to normal. Selenomethionine and D-pantethine demonstrated similar effect (Figure 5B). Thus, inhibition of doxorubicin-induced production of toxic superoxide anions under action of applied antioxidants also stopped the switching of apoptosis by this drug.

D-pantethine and selenomethionine inhibit oxidative stress induced in rat erythrocytes by doxorubicin action in vivo

Finally, we tried to confirm our conclusions from the treatment of tumor cells in vitro in an animal study on adult male Wistar rats. A redox-status of experimental animals and redox efficiency of applied compounds were evaluated by biochemical assays for analysis of glutathione system in rat erythrocytes. Nile blue sorption and methylene

| Parameter                      | Control | Dx     | D-pantethine +Dx | SeMet+Dx |
|--------------------------------|---------|--------|------------------|----------|
| Redox potential, mV            | 327.5 ±3.3 | 320.7 ±3.5* | 326.4 ±3.0* | 325.9 ±3.1* |

*P < 0.05 relative to the control. **P < 0.05 relative to Dx.

| Parameter                      | Control | Dx     | D-pantethine +Dx | SeMet+Dx |
|--------------------------------|---------|--------|------------------|----------|
| Sorption coefficient (NB), c.u. | 39.37 ±3.32 | 43.86 ±3.66* | 42.62 ±4.42 | 38.53 ±5.43 |
| Sorption coefficient (MB), c.u. | 8.80 ±0.69 | 9.87 ±0.95 | 9.28 ±0.99 | 9.21 ±1.17 |
| Sorption coefficient (NB), c.u./gHb | 132.1 ±8.9 | 141.2 ±17.0 | 132.8 ±17.5 | 127.7 ±13.4 |
| Sorption coefficient (MB), c.u./gHb | 296.3 ±3.1 | 318.4 ±4.5 | 288.3 ±3.3 | 30.7 ±4.0 |
| Absorption ratio (NB), %       | 84.8 ±1.1 | 86.2 ±1.0* | 85.8 ±1.4 | 84.4 ±1.9 |
| Absorption ratio (MB), %       | 74.5 ±1.5 | 76.6 ±1.8 | 75.4 ±2.0 | 75.2 ±2.3 |

*P < 0.05 relative to the control.

| Parameter                      | Control | Dx     | D-pantethine +Dx | SeMet+Dx |
|--------------------------------|---------|--------|------------------|----------|
| N,N-dimethyl-p-phenylenediamine conventional units /mL of blood plasma | 397.5 ±13.1 | 455.3 ±27.6* | 393.4 ±24.1* | 332.9 ±26.9* |
| Protein sulphydryl-groups      | µM/mL of blood plasma | µM/mg of protein |
| Control | 131.4 ±9.5 | 129.0 ±9.1 | 120.2 ±7.9* | 121.9 ±5.9 |
| Dx 5 mg/kg | 166 ±0.10 | 168 ±0.16 | 121 ±0.11* | 149 ±0.16* |
| D-pantethine +Dx | 105 ±0.10 | 121 ±0.11* | 121 ±0.11* | 121 ±0.11* |

*P < 0.05 relative to the control. **P < 0.05 relative to Dx.
blue adsorption were applied for estimation of plasma membrane damage of erythrocytes under the doxorubicin action. Doxorubicin treatment led to a decrease in the redox-potential of the erythrocytes, and it also sharply decreased GSH/GSSG ratio, while selenomethionine and D-pantethine rapidly restored both parameters almost to the control level (Table 1). Doxorubicin caused a small damage to plasma membranes of erythrocytes, as detected by Nile blue sorption (Table 2), but this damage was partially restored under the action of selenomethionine and D-pantethine (Table 2). Doxorubicin also induced oxidative stress (measured by an increase in the level of diphenylaminoreacting substances), which was eliminated by a simultaneous application of D-pantethine or selenomethionine (Table 3). Total (effective) redox potential in the erythrocytes was rapidly decreased under doxorubicin action, while selenomethionine totally blocked such action (Table 1). Surprisingly, a combined action of doxorubicin with D-pantethine led to a sharp decrease in the amount of protein sulphydryl groups in blood plasma of treated rats (Table 3).

### Table 4. Effect of intragastric administration of D-pantethine and selenomethionine (SeMet) on the contents of coenzyme A fractions (nmol/g of tissue) in the liver of rats under doxorubicin (Dx) treatment (CoA – coenzyme A) (mean ± standard deviation, n = 8)

|                  | Acid-soluble CoA | Short-chain acyls of CoA | Free CoA |
|------------------|------------------|--------------------------|----------|
| Control          | 292 ± 13         | 140 ± 9                  | 152 ± 8  |
| Doxorubicin      | 246 ± 12*        | 129 ± 7                  | 117 ± 5* |
| D-pantethine+Dx  | 258 ± 14         | 136 ± 8                  | 122 ± 6* |
| SeMet+Dx         | 262 ± 14         | 131 ± 7                  | 131 ± 7  |

*P < 0.05 relative to the control.

Multidirectional effects of D-pantethine and selenomethionine toward succinate dehydrogenase activity and coenzyme A content in the rat liver under doxorubicin action

In order to verify the involvement of mitochondrial oxidation processes in realization of toxic effect of doxorubicin, succinate dehydrogenase (SDH) activity in the liver of experimental animals was studied (Figure 6). A 2.5-fold decrease in the activity of this enzyme was detected under the action of doxorubicin, while D-pantethine restored it to control level. In contrast, there was no significant effect of selenomethionine on the SDH activity (Figure 6).

The content and ratio of CoA fractions are considered to be essential indicators of the enzymatic systems involved in energy metabolism and detoxification processes. Doxorubicin treatment led to a pronounced and significant drop in the fraction of free CoA, as well as of acid-soluble CoA in the rat liver tissue (Table 4). D-pantethine (CoA precursor) did not show any protective effect, whereas selenomethionine showed a trend toward normalization of the studied parameters (Table 4). Since these data were obtained by

---

**Figure 5.** Sodium selenite, selenomethionine, and D-pantethine inhibit production of superoxide anions (A) and induction of apoptosis (B) in human breast adenocarcinoma cells of MCF-7 line under doxorubicin treatment. 1 – control; 2 – doxorubicin, 1 µM; 3 – doxorubicin, 1 µM+ Na₂SeO₃, 0.1 µM; 4 – doxorubicin, 1 µM+selenomethionine, 0.1 µM; 5 – doxorubicin, 1 µM+D-pantethine, 25 µM.

**Figure 6.** D-pantethine, but not selenomethionine, restores the activity of succinate dehydrogenase (SDH) (nmol/mg protein* min) in the rat liver under doxorubicin treatment. *P < 0.05 relative to the control, triangle represents P < 0.05 relative to doxorubicin.
using cyclic phosphotransacetylase assay, they cannot exclude a direct effect of doxorubicin in that analytical system. To avoid this problem, HPLC study of the content of free form of CoA (CoA-SH) and a short-chain acyl-CoA derivative (acetyl-CoA) in the rat liver was carried out. The obtained results confirmed the CoA-mediated mechanism of cytotoxic action of doxorubicin and demonstrated highly protective effect of the D-pantethine and selenomethionine, which restored a quantity of both CoA-SH and acetyl-CoA to the control level (Figure 7).

**FIGURE 7.** Selenomethionine and D-pantethine restore content of coenzyme A-SH (A) and acetyl-coenzyme A (B) in the liver of normal rats after administration of doxorubicin. *P < 0.05 relative to doxorubicin.

**DISCUSSION**

Cardio- and nephrotoxicity of doxorubicin significantly limit its application in cancer chemotherapy. These negative side effects are caused by an excessive production of superoxide anions in the mitochondria of cells treated with doxorubicin (4). While the antitumor activity of this antibiotic is mainly implemented via inhibition of the DNA topoisomerase II (3), the induction of ROS is only a supplementary, and, at the same time, harmful mechanism accompanying doxorubicin action toward target cells, particularly those which contain a large number of mitochondria – cardiomyocytes and hepatocytes. This is why a search for new approaches capable of reducing the effects of the oxidative stress caused by the doxorubicin is essential for clinical medicine.

It is known that ROS are also involved in the mechanisms of anticancer activity of cisplatin, however, their impact is much weaker compared to the effect of doxorubicin (1). p53/ROS/p38α MAPK cascade was shown to be essential for cisplatin-induced cell death in HCT-116 cells (23). However, in our experiments antioxidants caused only a statistically insignificant decrease (7%) of cisplatin-induced anticancer action toward this cell line. We found that ROS scavengers did not affect the consequences of cisplatin treatment. Thus, their application together with cisplatin in chemotherapy regimens does not seem to be effective. In contrast, sodium selenite, selenomethionine, and D-pantethine significantly modulated cytotoxic activity of doxorubicin, thus, we studied doxorubicin action in more detail.

Although sodium selenite, selenomethionine, and D-pantethine possessed similar ROS scavenging activity both in vitro and in vivo, the molecular mechanisms of their action was different. We showed that all applied antioxidants modulated the effect of doxorubicin toward human colon carcinoma cells of HCT-116 line and human T-leukemia cells of Jurkat line via inhibiting cytotoxic activity of this drug by 15%-30%. It should be noted that a slight increase in sodium selenite and selenomethionine concentration from 0.1 µM to 0.25 µM (both were not toxic to target cells) significantly suppressed their cytoprotective effects, while higher doses of these compounds (5 µM, still low toxicity toward tumor cells in vitro) had an opposite effect, notably increasing doxorubicin toxicity (data not shown). Similar results – cytoprotective activity at low doses and enhancement of cytotoxic action at higher doses – were also observed for D-pantethine effect. To summarize, these results suggest an existence of different mechanisms of action of the studied antioxidants toward tumor cells depending on the concentration of these agents.

After finding that selenium-containing compounds partially decreased cytotoxic action of doxorubicin, but not that of cisplatin, toward tumor cell lines with different drug sensitivity, it was reasonable to study in more detail antioxidant modulation of the sensitivity of tumor cells with the MDR phenotype to doxorubicin and cisplatin.

Resistance acquisition of tumor cells to anticancer drugs is a serious problem in clinical practice. It was found that during one year of chemotherapy, resistance to anticancer
drugs develops in 30%-50% of cancer patients (24). Drug resistance is a multi-factorial and complex phenomenon (25), which results in a significant decrease in drug accumulation in cells by limiting their uptake, enhancing efflux, or affecting membrane lipids such as ceramide (26). These changes lead to: 1) inhibition of the programmed cell death (apoptosis) that is induced by most anticancer drugs (27); 2) activation of the mechanisms of general response that detoxify drugs and repair DNA damage (28); 3) alterations in cell cycle and its checkpoints that render cancer cells relatively resistant to cytotoxic effects of drugs. High expression of P-glycoprotein, MRP-1 protein, and bcrp in human tumors is considered to be the first sign of negative prognosis for cancer patients (10). Another mechanism of development of drug resistance is related to genetic defects in the structure of Bax and p53 genes, whose products play an important role in the regulation of cell cycle and apoptosis (29). Tumor cells with defects in these genes exhibit higher invasive potential, increased ability to metastasize, and are more resistant to chemotherapy (30).

Combined action of anticancer drug with sodium selenite, selenomethionine, and D-pantethine showed a cytoprotective activity toward tumor cell lines that are sensitive to the action of doxorubicin and a reverse effect (enhancing of cytotoxic activity of the doxorubicin) toward drug-resistant tumor cells with various defects (overexpression of P-glycoprotein or p53 and Bax knockouts). The dual activity of these antioxidants can be very important in clinical practice, since using these compounds as part of cancer chemotherapy regimens could reduce negative side effects of anticancer drugs toward normal cells and strengthen drug action in drug-resistant tumor cells.

Finally, we wanted to confirm our findings regarding cytoprotective effect of the selected antioxidants toward cultured mammalian cells treated with anticancer drugs in the in vivo experiments on rats treated with highly toxic doxorubicin combined with the physiological doses of selenomethionine and D-pantethine. In our studies, antioxidants and doxorubicin doses were selected on the basis of literature data (1). 1000 μg dose of L-selenomethionine/kg bw/d (equivalent to 400 μg selenium/kg bw/d) was reported to be a no-observed-adverse-level (NOAEL) in a 13-week study in rats (1). At the same time, no genotoxicity and no carcinogenicity has been observed for D-pantethine action, and no developmental toxicity in mice and rats at up to 600 mg/kg bw/d doses (31). 16 mg/kg of i.p. injected doxorubicin was its LD50 dose in rats (http://www.lclabs.com/MSDS/D-4000MSDS.php4). In the in vivo experiments, a cumulative dose of 1 mg/kg selenomethionine (5 daily gavages of 200 μg/kg), 2000 mg/kg dose of D-pantethine (5 daily gavages of 400 mg/kg), and 5 mg/kg dose of doxorubicin injected i.p. were used. 1:5 ratio for selenomethionine-doxorubicin and 1:400 ratio for doxorubicin-D-pantethine were applied. One can see that the used selenomethionine and D-pantethine doses are lower than the corresponding NOAEL doses, while the doxorubicin dose was 3 times lower than its LD50 in rats. Thus, no adverse effects of selenomethionine and D-pantethine alone were expected.

0.05-0.25 μM range of selenomethionine dose (depending on cell line sensitivity), 1-50 μM range of D-pantethine, and 0.5-5 μM dose of doxorubicin were applied in the in vitro experiments. Average ratio was 1:5 for selenomethionine:doxorubicin and 1:100 for doxorubicin:D-pantethine. Thus, the same ratio of selenomethionine and doxorubicin doses was applied in both in vitro and in vivo experiments in order to ensure the replicability of the obtained results. A 400:1 ratio of D-pantethine (2000 mg/kg) to doxorubicin (5 mg/kg) in the in vivo experiments was 4 times higher compared to the 100:1 ratio in vitro (50 μM of D-pantethine to 0.5 μM doxorubicin) due to non-toxicity of D-pantethine in mice.

The results of our in vivo studies in rats confirmed the results of in vitro studies on ROS-scavenging activity of sodium selenite and D-pantethine. Both these compounds blocked the induction of the oxidative stress in vivo. This was revealed by testing the restoration of redox-potential of erythrocytes and oxidative status of human plasma, which were increased under doxorubicin action. Besides, CoA level was restored in the liver of the experimental animals treated with doxorubicin. Selenomethionine did not have a statistically significant effect on the activity of SDH involved in Complex II of the mitochondrial respiratory chain of the liver, while D-pantethine strongly impacted the activity of that enzyme. This suggests various molecular mechanisms underlying cytoprotective activity of selenium derivatives and D-pantethine.

In conclusion, the obtained results suggest a high potential of using selenomethionine and D-pantethine in tumor chemotherapy regimens in combination with a very toxic drug – doxorubicin. A protective effect of the antioxidant agents during cytotoxic action of doxorubicin was demonstrated in vitro (cultured tumor cells) and in vivo (laboratory rats). In case of cisplatin, such effect was not pronounced. These results might be important
for planning further pre-clinical trials of the combinatory treatment schemes using anticancer drugs and specific antioxidant compounds.

Acknowledgments

The study was supported by Cedar Sinai Medical Center’s International Research and Innovation Management Program. The authors of this publication have no conflict of interest. The study was supported by joint Ukrainian-Belarusian grant financed by State Fund of Fundamental Research of Ukraine (#SFU15-185-2013) and State Fund of Fundamental Research of Belarus (№13K-138), and also by individual grants from West-Ukrainian Biomedical Center given to RP, LL, and VC.

Ethical approval

The study was supported by the Ethics Committee of the Center of Food, NAS of Belarus (Grodno Branch).

Authorship declaration

RP contributed to the conception of the study and interpretation of data, and drafted the manuscript. NS was involved in the studies of combined action of doxorubicin and antioxidants towards tumor cell lines. VC was involved in studies of combined action of doxorubicin and antioxidants towards tumor cell lines. LL performed cell culture and cytochemical studies (DAPI staining) and ROS measurement in MCF-7 cells under combined action of doxorubicin and antioxidants. SO contributed to animal studies and measurement of activity of specific enzymes in animal samples. VG performed HPLC study of CoA content in tissues of experimental animal studies and measurement of activity of specific enzymes in animal samples. V.G performed HPLC study of CoA content in tissues of experimental animal studies and measurement of activity of specific enzymes in animal samples. RP contributed to the conception of the study and interpretation of data, and revised the manuscript text.

Competing interests

All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization of the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References

1. Águilera F, Charrondiere UR, Dusemund B, Galtier P, Gilbert J, Gott DM, et al. L-selenomethionine as a source of selenium added for nutritional purposes to food supplements. The EFSA Journal. 2009;1082:1-39.

2. Berndtsson M, Hägg M, Panaretakis T, Havelka AM, Shoshan AM. Contribution to the conception of animal study of the action of antioxidants and doxorubicin and to interpretation of data obtained during in vivo studies. PH contributed to cell culture and drug-resistant tumor cell treatment with doxorubicin and antioxidants and performed the statistical analysis. WB provided drug-resistant tumor cell lines and analyzed the results of in vitro experiments of combined action of doxorubicin and antioxidants, and revised the manuscript text and figures. RS contributed in vivo experiments of combined action of doxorubicin and antioxidants, and revised the manuscript text.

3. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185-229. Medline:15169927 doi:10.1124/pr.56.2.6

4. Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2012;11 Suppl 1:S21-36. Medline:21635149 doi:10.1517/147440338.2011.589834

5. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007;7:3-18. Medline:17266502 doi:10.2174/187152007779314044

6. Slyshenkov VS, Moiseenok AG, Wojtczak L. Noxious effects of oxygen reactive species on energy-coupling processes in Ehrlich ascites tumor mitochondria and the protection by pantethenic acid. Free Radic Biol Med. 1996;20:793-800. Medline:8728026 doi:10.1016/0891-5849(95)02210-4

7. Tingii U. Selenium: its role as antioxidant in human health. Environ Health Prev Med. 2008;13:102-8. Medline:19568888 doi:10.1007/s12199-007-0019-4

8. Hu YJ, Chen Y, Zhang YQ, Zhou MZ, Song XM, Zhang BZ, et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res. 1997;56:331-41. Medline:9197929 doi:10.1007/BF02785304

9. Ciges M, Fernández-Cervilla F, Crespo PV, Campos A. Pantothentic acid and coenzyme A in experimental cisplatin-induced otoxicosis. Acta Otolaryngol. 1996;116:263-8. Medline:8725528 doi:10.3109/00016489609137837

10. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 1997;40 Suppl:S3-8. Medline:9272126 doi:10.1007/s002800051053

11. Carlberg L, Mannervik B. Glutathione reductase. Methods Enzymol. 1985;113:484-90. Medline:3003504 doi:10.1016/S0076-6879(85)13062-4

12. Rice-Evans CA, Diplock AT, Symons MC. Techniques in free radical research. Amsterdam: Elsevier; 1991.

13. Akerboom TPM, Sies H. Assay for glutathione and glutathione mixed disulfides in biological samples. Methods Enzymol. 1981;77:373-82. Medline:7329316 doi:10.1016/0076-6879(81)77050-2

14. Verde V, Fogliano V, Ritienni A, Maiani G, Morisco F, Caporaso N. Use of N,N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma. Free Radic Res. 2002;36:869-73. Medline:12420745 doi:10.1080/1071576021000005302

15. Verevkina IA, Tochilkin AI, Popova NA. Colorimetric method for determination of SH- and SS-groups in proteins connections using 5,5’-dithiobis (2-nitrobenzoic acid). In: Orekhovitch, editor. Modern methods in biochemistry [in Russian]. Moscow: Medicine; 1977. p. 223-31.

16. Yeshchenko ND, Volisky GG. Methods for biochemical studies [in Russian]. Leningrad: LSU; 1982.

17. Gavrilov VB, Kravchenko ON, Vetushko DA, Gurevich GL, Konev SV. A new method of estimating damage erythrocytes binding cationic dye [in Russian]. Reports of NAS of Belarus. 2000;44:87-90.

18. Togaybaev AA, Kurguzkina AV, Rikun IV, Karibzhanova PM. Method for diagnosing endogenous intoxication [in Russian]. Lab Delo. 1988;9:22-4. Medline:2464167

19. McDougal DB, Dargar RV. A spectrophotometric cycling assay for reduced coenzyme A and its esters in small amounts of tissue.
Abiko Y, Suzuki T, Shimizu M. Investigations on pantothenic acid and its related compounds. Biochemical studies (6). A final stage in the biosynthesis of CoA. J Biochem. 1967;61:309-12. Medline:6053310

Simon Hu, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 2000;5:415-8. Medline:11256682 doi:10.1023/A:1009612628304

Kaminsky VO, Zhivotovsky B. Free radicals in crosstalk between autophagy and apoptosis. Antioxid Redox Signal. 2014. Epub ahead of print. Medline:24359220 doi:10.1089/ars.2013.5746

Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis. 2007;12:1733-42. Medline:17505786 doi:10.1007/s10495-007-0082-8

Young RC. Drug resistance in cancer therapy. Dordrecht: Kluwer; 1989.

Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58. Medline:11902585 doi:10.1038/nrc706

Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001;15:719-30. Medline:11259390 doi:10.1096/fj.00-0223com

Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957-67. Medline:8402885 doi:10.1016/0092-8674(93)90719-7

Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med. 2001;7:584-90. Medline:11329060 doi:10.1038/87912

Chipuk JE, Kowala T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010-4. Medline:14963330 doi:10.1126/science.1092734

Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 2011;192:209-18. Medline:21263025 doi:10.1083/jcb.201009059

Aguilar F, Charrodiere UR, Dusemund B, Galtier P, Gilbert J, Gott DM, et al. Pantethine as source for pantothenic acid added as a nutritional substance in food supplements. The EFSJ. 2008;865:1-20.